company background image
OVID logo

Ovid Therapeutics NasdaqGS:OVID Stock Report

Last Price

US$0.29

Market Cap

US$20.7m

7D

1.8%

1Y

-90.3%

Updated

28 May, 2025

Data

Company Financials +

Ovid Therapeutics Inc.

NasdaqGS:OVID Stock Report

Market Cap: US$20.7m

OVID Stock Overview

A biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More details

OVID fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Revenue is forecast to grow 66.68% per year

Risk Analysis

Makes less than USD$1m in revenue ($548K)

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 19.5% per year for the next 3 years

Volatile share price over the past 3 months compared to the US market

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Ovid Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ovid Therapeutics
Historical stock prices
Current Share PriceUS$0.29
52 Week HighUS$3.31
52 Week LowUS$0.24
Beta0.27
1 Month Change-16.91%
3 Month Change-45.27%
1 Year Change-90.31%
3 Year Change-82.84%
5 Year Change-94.52%
Change since IPO-97.63%

Recent News & Updates

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13
Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09
We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16
Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20
Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18
Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01
We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25
Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21
Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Shareholder Returns

OVIDUS BiotechsUS Market
7D1.8%0.4%0.8%
1Y-90.3%-9.6%11.5%

Return vs Industry: OVID underperformed the US Biotechs industry which returned -10.4% over the past year.

Return vs Market: OVID underperformed the US Market which returned 11.3% over the past year.

Price Volatility

Is OVID's price volatile compared to industry and market?
OVID volatility
OVID Average Weekly Movement12.2%
Biotechs Industry Average Movement12.1%
Market Average Movement8.0%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market4.2%

Stable Share Price: OVID's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: OVID's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201423Jeremy Levinwww.ovidrx.com

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial.

Ovid Therapeutics Inc. Fundamentals Summary

How do Ovid Therapeutics's earnings and revenue compare to its market cap?
OVID fundamental statistics
Market capUS$20.72m
Earnings (TTM)-US$24.34m
Revenue (TTM)US$548.00k
37.7x
P/S Ratio
-0.8x
P/E Ratio

Is OVID overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OVID income statement (TTM)
RevenueUS$548.00k
Cost of RevenueUS$0
Gross ProfitUS$548.00k
Other ExpensesUS$24.89m
Earnings-US$24.34m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin100.00%
Net Profit Margin-4,441.42%
Debt/Equity Ratio0%

How did OVID perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 04:12
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ovid Therapeutics Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Thomas ShraderBTIG
Jason ButlerCitizens JMP Securities, LLC